Diana Spencer takes a look at two technological developments that have revolutionised the role of imaging in drug discovery. A range of traditional imaging modalities are applied in drug discovery. The development of functional magnetic resonance imaging (MRI), nanoparticles as contrast agents in computerised tomography (CT), ultrafast Doppler for ultrasound… Read More
A new multi-target partnership aims meet unmet need by designing antibodies for G-protein coupled receptors (GPCRs). The collaboration will combine Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-specific libraries’, with Nxera’s NxWave platform for GPCR target selection, validation and structural determination. Read More
The FDA’s approval of organoids in preclinical research has catalysed a major shift toward complex in vitro models (CIVM) for drug testing and disease research. The implementation of more biologically relevant phenotypic model formats, however, requires an evolution of imaging and analysis techniques. Traditional 2D high-content analysis (HCA)… Read More
Artificial intelligence (AI) and machine learning (ML) are helping drive efficiencies across drug discovery and development processes and represent exciting tools that teams can utilise to bring therapies to patients. Created by DDW and sponsored by Benchling, ‘AI & ML: How technology is improving drug discovery’ is a free… Read More
Created by DDW and sponsored by Benchling, ‘AI & ML: How technology is improving drug discovery’ is a free In Focus report available to download now. Artificial intelligence (AI) and machine learning (ML) are helping drive efficiencies across drug discovery and development processes and represent exciting tools that teams can… Read More
Megan Thomas comments and speaks with experts to uncover the future of cancer research. Artificial intelligence (AI) It’s not whether AI should be used, it’s when and how. Until several hurdles are overcome, such as data quality, data privacy and security, as well as regulatory and ethical challenges, this is… Read More
The FDA’s approval of organoids in preclinical research has catalysed a major shift toward complex in vitro models (CIVM) for drug testing and disease research. The implementation of more biologically relevant phenotypic model formats, however, requires an evolution of imaging and analysis techniques. Traditional 2D high-content analysis (HCA)… Read More
Dr Christine Allen, Co-Founder and CEO of Intrepid Labs tells Lu Rahman why the company’s technology has the ability to streamline the drug development process and improve the success rate of getting drugs to market. Intrepid Labs is the first spin-off from the University of Toronto’s Acceleration Consortium, which received… Read More
The FDA’s approval of organoids in preclinical research has catalysed a major shift toward complex in vitro models (CIVM) for drug testing and disease research. The implementation of more biologically relevant phenotypic model formats, however, requires an evolution of imaging and analysis techniques. Traditional 2D high-content analysis (HCA)… Read More
The FDA’s approval of organoids in preclinical research has catalysed a major shift toward complex in vitro models (CIVM) for drug testing and disease research. The implementation of more biologically relevant phenotypic model formats, however, requires an evolution of imaging and analysis techniques. Traditional 2D high-content analysis (HCA)… Read More
Optimism around the potential role for artificial intelligence (AI) in drug discovery continues, with recent financial deals supporting its use in developing therapeutics for age-related diseases, GPCR-targeting antibodies, DUB-modulating compounds, and novel fusion proteins. AI simulation to advance therapeutics for age-related diseases Biotech Shift Bioscience… Read More
The Pistoia Alliance has released the results of its annual Lab of the Future survey, conducted in partnership with Open Pharma Research. The survey of 200 experts spanning Europe, the Americas and APAC was presented at the Lab of the Future Congress in Amsterdam from 1-2 October 2024. … Read More
The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Recently, the Society for Neuroscience’s annual meeting took place, so… Read More
The FDA’s approval of organoids in preclinical research has catalysed a major shift toward complex in vitro models (CIVM) for drug testing and disease research. The implementation of more biologically relevant phenotypic model formats, however, requires an evolution of imaging and analysis techniques. Traditional 2D high-content analysis (HCA) approaches fall… Read More
Several recent drug discovery partnerships have been announced that reflect the importance of new technologies and techniques to the efficient development of new therapeutics. ERS Genomics and Université de Montréal ERS Genomics and Université de Montréal (UdeM) have announced an agreement that grants the university access… Read More
News round-up for 7-11 October by DDW Senior Digital Content Editor Diana Spencer. The Society for Neuroscience annual meeting took place this week, so the headlines have been dominated by the latest discoveries related to the brain and the central nervous system, including significant findings related to GLP-1… Read More
